# Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

> **NCT00868634** · PHASE3 · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 600 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** bevacizumab
- **DRUG:** vinorelbine

## Key facts

- **NCT ID:** NCT00868634
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2014-03
- **Final completion:** 2015-10
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2016-08-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868634, "Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00868634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*